Roth sitting on $4.50

http://www.viralytics.com/wp-conten...date-Report-ROTH-Capital-14-November-2016.pdf

We are impressed by the first CAPRA look and believe both it and the recent MITCI update (CAVATAK + Yervoy) continue to strengthen the company's position.

A major takeaway, in our belief, is that the data represent an impressive translation from preclinical models to the clinical setting. While patient numbers are small, the response rates point to synergy of the two agents and the combination was safe and well tolerated. Reiterate Buy / A $4.50 target.